Novavax Inc. research and ratings by Barron's. View NVAX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

A new Cambridge biotech is creating a roadmap to expand preventive health to a broader range of diseases, treating patients before they become irreversibly ill.

Peter Kotlár has long promoted fringe theories about mRNA vaccines, claiming they "cause the human body to produce toxins." ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

A middle school student north of Dallas has tested positive. Meanwhile, Illinois has confirmed its first case in the state. Plus: A study in mice shows that covid is still contagious a week or more ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

Thousands of children, women and senior citizens in Calbayog, Samar are set to receive various vaccines as part of the ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $28.00. The ...

AIIMS Raipur has successfully performed its first Swap Kidney Transplant, also known as a Kidney Paired Transplant (KPT), the ...

Novavax’s vaccine, which is the only protein-based COVID-19 vaccine, is awaiting for its full approval. Once approved, it ...